Australia's Jurox launches anesthetic in U.S. two months after setting up American operations

Australia's Jurox, which set up its U.S. headquarters in June, is launching its Alfaxan intravenous injectable anesthetic in the U.S. for use in cats and dogs. It will be available by veterinary prescription beginning Aug. 25. Available in 20 countries worldwide, alfaxalone is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic.

With its U.S. headquarters in Kansas City, MO, Jurox is supported by a team of 32--with 6 veterinarians. It will be partnering with 6 veterinary distributors to ensure national coverage. Alfaxan will be available through Henry Schein, MWI, Patterson, NEVSCo, Midwest Veterinary Supply and Victor Medical.

"We are pleased to finally be in a position to bring our innovative product to the world's largest market. Since beginning this process [of registration] we have had countless inquiries as to why it has not been available to U.S. veterinarians," Jurox CEO J.J. O'Brien said in a statement.

Jurox is a family-owned vet pharmaceutical company that manufactures and markets some 120 proprietary animal health products. Its headquarters are in Hunter Valley, Australia. Jurox has commercial operations in New Zealand and the U.K. as well as the U.S.

Jurox's launch of alfaxalone also comes a week after Irwindale, CA-based Bimeda announced the launch of its XylaMed (xylazine) product, an injectable sedative and analgesic for use in horses and Cervidae.

- here's the release
- here's more about XylaMed

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…